Let’s chat about Clinical Trial Readiness with a focus on Ataxia. Clinical trials ensure that treatments are safe and effective before they gain approval for widespread use in humans. Clinical trials test new treatments and therapies including: new drugs, different use for an already approved drug, medical devices, new treatment/therapy Read More…
We’re excited to announce the launch of a search for NAF’s first Chief Scientific Officer. This exciting role is new for NAF and will be instrumental in shaping our research funding strategy and deepening our rapidly expanding partnerships in the pharmaceutical space. The Ataxia community is at a pivotal moment Read More…
NAF, FARA, and more than 100 volunteer advocates will come together to raise awareness about Ataxia and supporting legislation that directly impacts our community. The third United Against Ataxia Hill Day will be held on Wednesday, September 29, 2021. Ataxia advocates will speak to their Congressional Members to make the Read More…
What does a placebo mean? A placebo is a simulated substance that has no therapeutic effect or active ingredients. Often, a placebo looks, feels, and tastes like other therapies being tested in the clinical trial. What is the placebo effect, and why is it important? https://www.youtube.com/watch?v=5RhG_ySxhDA Why are placebo-controlled Read More…
Author: Sue Hagen, Research Services Director I recently attended the virtual annual meeting of the Drug Information Association. I took in four days of sessions, all relating to topics of interest to all stakeholders involved in drug discovery and development. My head is still spinning! While you would think that Read More…
What is an Informed Consent Form (ICF)? Informed Consent Forms are important aspect of a clinical trial. An ICF is a document that provides a potential clinical trial participant information about the clinical trial and any risks there may be in participating. The goal behind the ICF is to present Read More…
NAF is committed to providing the resources to fund research needed to develop treatments and therapies for people with Ataxia. We fund research studies ranging from $35,000-$100,000 per study. We are accepting Letters of Intent for research grants through late September and early October on proposalCENTRAL. For more information visit www.ataxia.org/researcher-resources. If you Read More…
Guest Authors: Drs. Paulson, Ashizawa, and Öz Right now, it’s an exciting time in the Ataxia field. Many companies are working rapidly to bring therapies to the clinic for the Spinocerebellar Ataxias (SCAs). Unfortunately, however, we still need to know more about the natural history of SCA and relevant biomarkers Read More…
Author: Sue Hagen, Research Services Director In the 14 years that I have been on staff at the National Ataxia Foundation, I have heard many times that clinical trials for therapy development for Ataxia will start within the next 5 years. And I have seen the Ataxia community patiently and Read More…
Guest Author: Sam Kirton, NAF Board of Directors President Fighting Ataxia is a cause that is close to Sam Kirton’s heart. He lost several family members to the disease. He volunteers his time to help make sure that NAF continues to move boldly forward, championing efforts to accelerate development of Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
Physical Address:
600 Highway 169 South
Suite 1725
Minneapolis, MN 55426
Mailing Address:
PO Box 27986
Golden Valley, MN 55427
763-553-0020
763-553-0167 (Fax)
